

Active Biotech Q4 2024 - Funded through 2025

Redeye comments on Active Biotech's Q4 report. The main event in the quarter was the oversubscribed rights issue. Laquinimod's biodistribution study is the next main trigger while tasquinimod is slowly approaching the recruitment of the first patients in myelofibrosis.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Active Biotech Q4 2024 - Funded through 2025](#)